Is Cannabis Becoming More Potent?

Autor: Tom P. Freeman, Sam Craft

Publikováno v: Marijuana and Madness ISBN: 9781108943246

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bad13fc27bca523b026d97bbe37378a0
https://doi.org/10.1017/9781108943246.006

Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act

Autor: Sam Craft, Michael Dunn, Dan Vidler, Jane Officer, Ian S. Blagbrough, Christopher R. Pudney, Graeme Henderson, Ahmed Abouzeid, Paul I. Dargan, Michael Eddleston, Jamie Cooper, Simon L. Hill, Clair Roper, Tom P. Freeman, Simon H. L. Thomas

Publikováno v: Craft, S, Dunn, M, Vidler, D, Officer, J, Blagbrough, I S, Pudney, C R, Henderson, G, Abouzeid, A, Dargan, P I, Eddleston, M, Cooper, J, Hill, S L, Roper, C, Freeman, T P & Thomas, S H L 2022, ' Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act ', Addiction . https://doi.org/10.1111/add.15967
Craft, S, Dunn, M, Vidler, D, Officer, J, Blagbrough, I S, Pudney, C R, Henderson, G, Abouzeid, A, Dargan, P I, Eddleston, M, Cooper, J, Hill, S L, Roper, C, Freeman, T P & Thomas, S H L 2022, ' Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act ', Addiction, vol. 117, no. 11, pp. 2899-2906 . https://doi.org/10.1111/add.15967

BACKGROUND AND AIMS: The United Kingdom (UK) Psychoactive Substances Act (PSA), implemented on the 26 th May 2016, made the production, supply and sale of all non-exempted psychoactive substances illegal. The aim of this study was to measure trends i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293522550a611059eb3cbb392fae0f79
https://hdl.handle.net/20.500.11820/1147a3e7-91ca-4eba-809e-a5d1ce630703

Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis

Autor: Sam, Craft, Jason A, Ferris, Monica J, Barratt, Larissa J, Maier, Michael T, Lynskey, Adam R, Winstock, Tom P, Freeman

Publikováno v: Psychopharmacology. 239(5)

Synthetic cannabinoid receptor agonists (SCRAs) may be used as an alternative to natural cannabis; however, they may carry a greater risk of problematic use and withdrawal. This study aimed to characterise the withdrawal symptom profile of SCRAs and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::88c58c1faaef1ceea9a9cbdae77e7b73
https://pubmed.ncbi.nlm.nih.gov/34533608

A latent class analysis of cannabis use products in a general population sample of adolescents and their association with paranoia, hallucinations, cognitive disorganisation and grandiosity

Autor: Thalia Escamilla De La Torre, Jack Wilson, Michael T. Lynskey, Sam Craft, Tom P. Freeman, Clare Mackie

Publikováno v: Mackie, C J, Wilson, J, Freeman, T P, Craft, S, Escamilla De La Torre, T & Lynskey, M T 2021, ' A latent class analysis of cannabis use products in a general population sample of adolescents and their association with paranoia, hallucinations, cognitive disorganisation and grandiosity ', Addictive Behaviors, vol. 117, 106837 . https://doi.org/10.1016/j.addbeh.2021.106837

Adolescents have access to a wide range of cannabis products with patterns of use becoming increasingly diverse. This study aimed to identify subgroups of adolescents in the general population who use similar types of cannabis and their association w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a32385f04c5a415e7a5d9019051feb
https://pubmed.ncbi.nlm.nih.gov/33545621

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial

Autor: Celia J. A. Morgan, H. Valerie Curran, Dominic O'Ryan, Michael A P Bloomfield, Emily Thomas, Danica Astbury, Jane Kinghorn, Paul D. Morrison, Abigail Freeman, Rachel Lees, Ali Mofeez, Gianluca Baio, Chandni Hindocha, Sam Craft, Natacha D C Shaban, Tom P. Freeman

Publikováno v: Freeman, T, Hindocha, C, Baio, G, Shaban, N, Thomas, E, Astbury, D, Freeman, A, Lees, R H, Craft, S, Morrison, P, Bloomfield, M, O'Ryan, D, Kinghorn, J, Morgan, C, Mofeez, A & Curran, H V 2020, ' Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial ', The Lancet Psychiatry, vol. 7, no. 10, pp. 865-874 . https://doi.org/10.1016/S2215-0366(20)30290-X
Lancet Psychiatry

Summary Background A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to ide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897993dc0667b7e55e07c347c7bafe79
https://pubmed.ncbi.nlm.nih.gov/32949514